HK1100326A1 - Guanidine compounds, and use thereof as binding partners for 5-ht5 receptors 5-ht5 - Google Patents
Guanidine compounds, and use thereof as binding partners for 5-ht5 receptors 5-ht5Info
- Publication number
- HK1100326A1 HK1100326A1 HK07104632.9A HK07104632A HK1100326A1 HK 1100326 A1 HK1100326 A1 HK 1100326A1 HK 07104632 A HK07104632 A HK 07104632A HK 1100326 A1 HK1100326 A1 HK 1100326A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- receptors
- binding partners
- guanidine compounds
- guanidine
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/28—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004008141A DE102004008141A1 (de) | 2004-02-19 | 2004-02-19 | Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren |
PCT/EP2005/001521 WO2005082871A2 (de) | 2004-02-19 | 2005-02-15 | Guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1100326A1 true HK1100326A1 (en) | 2007-09-14 |
Family
ID=34813497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07104632.9A HK1100326A1 (en) | 2004-02-19 | 2007-04-30 | Guanidine compounds, and use thereof as binding partners for 5-ht5 receptors 5-ht5 |
Country Status (8)
Country | Link |
---|---|
US (4) | US8431604B2 (es) |
EP (4) | EP2380885A1 (es) |
JP (1) | JP4658073B2 (es) |
DE (1) | DE102004008141A1 (es) |
ES (1) | ES2494918T3 (es) |
HK (1) | HK1100326A1 (es) |
MX (1) | MXPA06009434A (es) |
WO (1) | WO2005082871A2 (es) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
ES2300568T3 (es) | 2002-03-20 | 2008-06-16 | Mannkind Corporation | Aparato de inhalacion. |
DE10259382A1 (de) * | 2002-12-18 | 2004-07-01 | Abbott Gmbh & Co. Kg | 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung |
DE602005024413D1 (de) | 2004-08-20 | 2010-12-09 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
AU2005277041B2 (en) | 2004-08-23 | 2012-03-22 | Mannkind Corporation | Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery |
US9296697B2 (en) | 2005-08-24 | 2016-03-29 | Abbott Laboratories | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors |
US7799344B2 (en) | 2005-09-14 | 2010-09-21 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
CN104383546B (zh) | 2006-02-22 | 2021-03-02 | 曼金德公司 | 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法 |
TW200808751A (en) * | 2006-04-13 | 2008-02-16 | Astrazeneca Ab | New compounds |
US7526886B2 (en) * | 2006-10-24 | 2009-05-05 | Esco Corporation | Wear assembly for an excavating bucket |
CA2669590A1 (en) | 2006-12-07 | 2008-06-12 | F. Hoffmann-La Roche Ag | 2-aminoquinolines as 5-ht(5a) receptor antagonists |
EP2177505A4 (en) | 2007-08-10 | 2011-08-31 | Astellas Pharma Inc | BICYCLIC ACYLGUANIDINE DERIVATIVE |
KR101192952B1 (ko) * | 2007-09-27 | 2012-10-18 | 에프. 호프만-라 로슈 아게 | 5-ht5a 수용체 길항제로서의 퀴놀린 유도체 |
US8785396B2 (en) * | 2007-10-24 | 2014-07-22 | Mannkind Corporation | Method and composition for treating migraines |
CN101959876A (zh) | 2008-03-05 | 2011-01-26 | 弗·哈夫曼-拉罗切有限公司 | 2-氨基喹啉类化合物 |
JP2011514898A (ja) | 2008-03-07 | 2011-05-12 | エフ.ホフマン−ラ ロシュ アーゲー | 2−アミノキノリン誘導体 |
MX2010009643A (es) | 2008-03-07 | 2010-09-22 | Hoffmann La Roche | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). |
KR20100119789A (ko) | 2008-03-07 | 2010-11-10 | 에프. 호프만-라 로슈 아게 | 2-아미노퀴놀린 |
CA2716907A1 (en) | 2008-03-12 | 2009-09-17 | F. Hoffmann-La Roche Ag | 2-aminoquinolines as 5-ht5a receptor antagonists |
US8499757B2 (en) | 2008-06-13 | 2013-08-06 | Mannkind Corporation | Dry powder inhaler and system for drug delivery |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
JP5479465B2 (ja) | 2008-06-20 | 2014-04-23 | マンカインド コーポレイション | 吸入努力をリアルタイムにプロファイルする対話式機器および方法 |
US8134000B2 (en) | 2008-07-14 | 2012-03-13 | Gilead Sciences, Inc. | Imidazolyl pyrimidine inhibitor compounds |
US8124764B2 (en) | 2008-07-14 | 2012-02-28 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitor compounds |
EP2303841A1 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
KR20110038159A (ko) | 2008-07-28 | 2011-04-13 | 길리애드 사이언시즈, 인코포레이티드 | 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물 |
TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
EP2676695A3 (en) | 2009-03-11 | 2017-03-01 | MannKind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
EP2440517B1 (en) | 2009-06-08 | 2014-03-26 | Gilead Sciences, Inc. | Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds |
CN102459159A (zh) | 2009-06-08 | 2012-05-16 | 吉利德科学股份有限公司 | 烷酰基氨基苯甲酰胺苯胺hdac抑制剂化合物 |
US8741534B2 (en) * | 2009-06-08 | 2014-06-03 | Xerox Corporation | Efficient solvent-based phase inversion emulsification process with defoamer |
KR20190090092A (ko) | 2009-06-12 | 2019-07-31 | 맨카인드 코포레이션 | 한정된 비표면적을 갖는 디케토피페라진 마이크로입자 |
TW201116281A (en) | 2009-08-06 | 2011-05-16 | Astellas Pharma Inc | N atom containing ring acylguanidine derivatives |
JP5784622B2 (ja) | 2009-11-03 | 2015-09-24 | マンカインド コーポレ−ション | 吸入活動をシミュレートするための装置及び方法 |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
WO2011133920A1 (en) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
CN102985125A (zh) | 2010-06-21 | 2013-03-20 | 曼金德公司 | 干粉药物输送系统和方法 |
US9169199B2 (en) | 2010-12-08 | 2015-10-27 | Lycera Corporation | Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
HUE035881T2 (en) | 2010-12-08 | 2018-05-28 | Lycera Corp | Pyrazolyl-guanidine-F1F0-inhibitors and their therapeutic use |
CA2820044A1 (en) | 2010-12-08 | 2012-06-14 | Lycera Corporation | Pyridonyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
BR122020008875B8 (pt) | 2011-04-01 | 2022-12-06 | Mannkind Corp | Embalagem de bolha e método de fabricação de uma embalagem de bolhas |
US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
BR112014009686A2 (pt) | 2011-10-24 | 2018-08-07 | Mannkind Corp | composição analgésica inalável, pó seco e método para tratar dor |
WO2013146754A1 (ja) * | 2012-03-27 | 2013-10-03 | 塩野義製薬株式会社 | Trpv4阻害活性を有する芳香族複素5員環誘導体 |
US9221814B2 (en) | 2012-06-08 | 2015-12-29 | Lycera Corporation | Heterocyclic guanidine F1F0-atpase inhibitors and therapeutic uses thereof |
EP2861225A4 (en) | 2012-06-08 | 2015-11-18 | Lycera Corp | Saturated acylguanidine for the inhibition of F1F0-ATPASE |
WO2013185045A1 (en) | 2012-06-08 | 2013-12-12 | Lycera Corporation | Indazole guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
ES2624294T3 (es) | 2012-07-12 | 2017-07-13 | Mannkind Corporation | Sistemas de suministro de fármacos en polvo seco |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
TWI644899B (zh) | 2013-02-04 | 2018-12-21 | 健生藥品公司 | Flap調節劑 |
EP3495359A1 (en) | 2013-02-04 | 2019-06-12 | Janssen Pharmaceutica NV | Flap modulators |
CA2906817C (en) | 2013-03-15 | 2022-01-18 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
US9745274B2 (en) | 2013-07-03 | 2017-08-29 | Shin Nippon Biomedical Laboratories, Ltd. | Compound, organic cation transporter 3 detection agent, and organic cation transporter 3 activity inhibitor |
US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
CN105517607A (zh) | 2013-08-05 | 2016-04-20 | 曼金德公司 | 吹入设备和方法 |
CA2931851A1 (en) | 2013-12-10 | 2015-06-18 | Lycera Corporation | Trifluoromethyl pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
US9815791B2 (en) | 2013-12-10 | 2017-11-14 | Lycera Corporation | Alkylpyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof |
EP3080087B1 (en) | 2013-12-10 | 2019-05-22 | Lycera Corporation | N-substituted pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
CN108137545B (zh) | 2015-05-20 | 2020-09-22 | 美国安进公司 | Apj受体的三唑激动剂 |
WO2017093019A1 (en) | 2015-12-03 | 2017-06-08 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
EP3452466B1 (en) | 2016-05-03 | 2020-08-12 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
WO2018097944A1 (en) | 2016-11-16 | 2018-05-31 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
US11191762B2 (en) | 2016-11-16 | 2021-12-07 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the APJ Receptor |
US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
US11020395B2 (en) | 2016-11-16 | 2021-06-01 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor |
WO2018093580A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
US11149040B2 (en) | 2017-11-03 | 2021-10-19 | Amgen Inc. | Fused triazole agonists of the APJ receptor |
US11807624B2 (en) | 2018-05-01 | 2023-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the APJ receptor |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1031165A (en) * | 1965-08-18 | 1966-05-25 | Wellcome Found | Guanidines, isoureas and isothioureas |
US3562258A (en) * | 1969-02-10 | 1971-02-09 | Nordmark Werke Gmbh | (**1-(p-amino benzene sulfonyl)-n**3-(4,5-dimethyl oxazolyl-(2)) guanidine |
DE2205744A1 (de) | 1972-02-08 | 1973-08-09 | Thomae Gmbh Dr K | Neue durch einen guanidinylidenrest substituierte heterocyclen und verfahren zu ihrer herstellung |
AU7593174A (en) | 1973-12-12 | 1976-06-03 | Wilkinson Sword Ltd | Compounds having a physiological cooling effect |
US4089965A (en) | 1976-03-26 | 1978-05-16 | American Cyanamid Company | Thiazolylphenylguanidines as antirhinovirus agents |
BE850148A (fr) | 1977-01-06 | 1977-07-06 | American Cyanamid Co | Procede pour prevoir ou traiter les infections a rhinovirus |
NL7700083A (en) | 1977-01-06 | 1978-07-10 | American Cyanamid Co | Antiviral thiazolyl-guanidine compsns. - for treating respiratory infections caused by rhinovirus, also for coxsackie and polio virus infections |
EP0003640B1 (en) | 1978-01-18 | 1982-01-27 | Imperial Chemical Industries Plc | Antisecretory guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them |
EP0018107B1 (en) * | 1979-04-20 | 1982-12-22 | Beecham Group Plc | Oxazoline and thiazoline derivatives, processes for their preparation and pharmaceutical compositions containing them |
EP0028883A3 (en) * | 1979-11-10 | 1981-06-03 | Beecham Group Plc | Benzimidazoline derivatives, processes for their preparation and pharmaceutical compositions containing them |
JPS5936674A (ja) * | 1982-08-25 | 1984-02-28 | Yamanouchi Pharmaceut Co Ltd | N−置換グアニジノチアゾ−ル誘導体およびその製造法 |
JPS59225186A (ja) | 1983-05-18 | 1984-12-18 | Yamanouchi Pharmaceut Co Ltd | 新規なグアニジノチアゾ−ル誘導体及びその製造方法 |
JPS59225172A (ja) | 1983-06-03 | 1984-12-18 | Yamanouchi Pharmaceut Co Ltd | 新規グアニジノチアゾ−ル誘導体及びその製法 |
US4560690A (en) * | 1984-04-30 | 1985-12-24 | Pfizer Inc. | 2-(N-substituted guanidino)-4-hetero-arylthiazole antiulcer agents |
US4814341A (en) | 1986-08-26 | 1989-03-21 | Reiter Lawrence A | 2-guanidino-4-(2-furyl) thiazoles as antiulcer agents |
EP0259085B1 (en) | 1986-08-29 | 1991-08-21 | Pfizer Inc. | 2-guanidino-4-arylthiazoles for treatment of peptic ulcers |
JPH0240671A (ja) | 1988-08-01 | 1990-02-09 | Minolta Camera Co Ltd | 現像装置 |
IL91152A0 (en) | 1988-08-15 | 1990-03-19 | Fujisawa Pharmaceutical Co | Furylthiazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
IL95548A0 (en) | 1989-09-15 | 1991-06-30 | Fujisawa Pharmaceutical Co | Thiazole derivatives,processes for the preparation thereof and pharmaceutical composition containing the same |
CA2105981A1 (en) | 1991-03-13 | 1992-09-14 | Hisashi Takasugi | Thiazole derivatives |
US5512588A (en) | 1991-08-02 | 1996-04-30 | Fujisawa Pharmaceutical Co., Ltd. | Furylthiazoles and their use as H2 - receptor antagonists and antimicrobials |
GB9125970D0 (en) * | 1991-12-06 | 1992-02-05 | Fujisawa Pharmaceutical Co | New compounds |
GB9211163D0 (en) | 1992-05-26 | 1992-07-08 | Fujisawa Pharmaceutical Co | New oxazole derivatives |
GB9219472D0 (en) * | 1992-09-15 | 1992-10-28 | Leo Pharm Prod Ltd | Chemical compounds |
GB9311613D0 (en) | 1993-06-04 | 1993-07-21 | Fujisawa Pharmaceutical Co | Thienylthiazole derivatives |
JPH07188197A (ja) | 1993-11-17 | 1995-07-25 | Fujisawa Pharmaceut Co Ltd | オキサゾール誘導体 |
GB9326611D0 (en) * | 1993-12-31 | 1994-03-02 | Fujisawa Pharmaceutical Co | New compound |
JP2788856B2 (ja) | 1994-07-01 | 1998-08-20 | 株式会社日本製鋼所 | ポリ乳酸プラスチック磁石成形材料および磁石製品の製造方法 |
GB9416459D0 (en) | 1994-08-15 | 1994-10-05 | Fujisawa Pharmaceutical Co | New compounds |
GB9504689D0 (en) | 1995-03-08 | 1995-04-26 | Fujisawa Pharmaceutical Co | Thienylthiazole deriratives |
JPH08337579A (ja) * | 1995-06-14 | 1996-12-24 | Fujisawa Pharmaceut Co Ltd | グアニジノチアゾ−ルおよびその抗潰瘍剤、h2−受容体拮抗剤および抗菌剤としての用途 |
JPH095722A (ja) * | 1995-06-14 | 1997-01-10 | Nikko Kogyo Kk | 液晶パネル保持枠 |
JPH0940671A (ja) | 1995-07-28 | 1997-02-10 | Fujisawa Pharmaceut Co Ltd | フリルチアゾール化合物およびその用途 |
CN1138764C (zh) | 1997-04-21 | 2004-02-18 | 住友制药株式会社 | 异噁唑衍生物 |
DE19719053A1 (de) | 1997-05-06 | 1998-11-12 | Bayer Ag | Substituierte Aminothiazole |
MA26540A1 (fr) | 1997-09-04 | 2004-12-20 | Smithkline Beecham Corp | Composes nouveaux inhibiteurs de proteases et compositions pharmaceutiques les contenant. |
ES2297897T3 (es) * | 1997-10-21 | 2008-05-01 | Wyeth | Compuestos farmaceuticamente activos y metodos de uso. |
DE19900674A1 (de) | 1999-01-11 | 2000-07-13 | Basf Ag | Bindungspartner für 5-HT5-Rezeptoren zur Migränebehandlung |
DE19900673A1 (de) | 1999-01-11 | 2000-07-13 | Basf Ag | Verwendung von Bindungspartnern für 5-HT5-Rezeptoren zur Behandlung neurodegenerativer und neuropsychiatrischer Störungen |
MXPA03001535A (es) | 2000-08-21 | 2004-12-13 | Pacific Corp | Derivados de tiourea novedosos y las composiciones farmaceuticas que contienen los mismos. |
PE20021046A1 (es) | 2000-09-30 | 2002-12-14 | Gruenenthal Chemie | Sulfonilguanidina que tiene afinidad al punto de fijacion de gabapentina |
JP4783496B2 (ja) * | 2000-11-02 | 2011-09-28 | 株式会社トクヤマ | アミノ酸誘導体の光学異性体の分離方法 |
EP1450901A4 (en) * | 2001-12-10 | 2005-05-25 | Bristol Myers Squibb Co | (1-PHENYL-2-HETEROARYL) ETHYL-GUANIDINE COMPOUNDS AS AN INHIBITORS OF MITOCHONDRIAL F1F0 ATP HYDROLASE |
US7868028B2 (en) | 2002-06-17 | 2011-01-11 | Fred Drasner | Guanidine compounds as anesthetics and for treatment of nervous system disorders |
-
2004
- 2004-02-19 DE DE102004008141A patent/DE102004008141A1/de not_active Withdrawn
-
2005
- 2005-02-15 EP EP11002549A patent/EP2380885A1/de not_active Withdrawn
- 2005-02-15 EP EP11002516A patent/EP2366697A1/de not_active Withdrawn
- 2005-02-15 EP EP11002515A patent/EP2366392A1/de not_active Withdrawn
- 2005-02-15 EP EP05707406.4A patent/EP1716127B1/de active Active
- 2005-02-15 MX MXPA06009434A patent/MXPA06009434A/es active IP Right Grant
- 2005-02-15 ES ES05707406.4T patent/ES2494918T3/es active Active
- 2005-02-15 US US10/590,265 patent/US8431604B2/en not_active Expired - Fee Related
- 2005-02-15 WO PCT/EP2005/001521 patent/WO2005082871A2/de active Application Filing
- 2005-02-15 JP JP2006553516A patent/JP4658073B2/ja not_active Expired - Fee Related
-
2007
- 2007-04-30 HK HK07104632.9A patent/HK1100326A1/xx not_active IP Right Cessation
-
2011
- 2011-02-04 US US13/021,336 patent/US8481576B2/en active Active
-
2012
- 2012-11-21 US US13/683,296 patent/US9475782B2/en not_active Expired - Fee Related
-
2016
- 2016-10-24 US US15/332,744 patent/US20170037016A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2366392A1 (de) | 2011-09-21 |
US9475782B2 (en) | 2016-10-25 |
US8431604B2 (en) | 2013-04-30 |
US20130324537A1 (en) | 2013-12-05 |
EP2380885A1 (de) | 2011-10-26 |
WO2005082871A3 (de) | 2005-11-10 |
US20110237589A1 (en) | 2011-09-29 |
US8481576B2 (en) | 2013-07-09 |
EP1716127A2 (de) | 2006-11-02 |
US20170037016A1 (en) | 2017-02-09 |
ES2494918T3 (es) | 2014-09-16 |
JP4658073B2 (ja) | 2011-03-23 |
EP2366697A1 (de) | 2011-09-21 |
US20070299074A1 (en) | 2007-12-27 |
EP1716127B1 (de) | 2014-08-06 |
DE102004008141A1 (de) | 2005-09-01 |
MXPA06009434A (es) | 2007-03-21 |
WO2005082871A2 (de) | 2005-09-09 |
JP2007523113A (ja) | 2007-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1100326A1 (en) | Guanidine compounds, and use thereof as binding partners for 5-ht5 receptors 5-ht5 | |
PL1844337T3 (pl) | Związki wiążące, związki immunogenne i peptydomimetyki | |
EP1827245A4 (en) | BINDING COMPONENT | |
EP1745800A4 (en) | NEW BLT2-MEDIATED DISEASE AND BLT2 BINDING AND CONNECTION | |
IL207954A0 (en) | T1r hetero-oligomeric taste receptors, binding compounds and uses thereof | |
EP1760071A4 (en) | COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF | |
IL178989A0 (en) | Guanidine based composition and system for same | |
GB2437186B (en) | Saftey joint | |
AP2006003659A0 (en) | Azabenzofuran substituted thioureas, inhibitors ofviral replication | |
EP1712802A4 (en) | CONNECTING UNIT FOR FLAT WORKPIECES | |
IL184048A0 (en) | Triazolone, tetrazolone and imidazolone derivatives for use as alpha-2c adrenoreceptor antagonists | |
TWI367222B (en) | Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof | |
IL184137A0 (en) | Binding implement for document | |
GB0415538D0 (en) | Functional hand splint | |
DK1778265T3 (da) | Guanylhydrazoneforbindelser, sammensætninger, fremgangsmåder og anvendelse | |
EP1932681A4 (en) | BINDER | |
GB0506496D0 (en) | Compound, composition and use | |
GB0410627D0 (en) | Specific binding members | |
ZA200609215B (en) | Guanidine based composition and system for same | |
GB2444005B (en) | Compound, composition and use | |
ZA200701801B (en) | Benzamide compounds | |
GB0413444D0 (en) | Easy nail filer | |
HU0400798D0 (en) | Folder | |
GB0426795D0 (en) | Manicure file | |
GB0416402D0 (en) | Specific binding members against synaptophysin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190215 |